Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4820 - Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Jenny Lee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

J.H. Lee1, S.Y. Lim2, A.M. Menzies3, M.S. Carlino4, A.D. Guminski3, K. Nahar5, D. Palmieri6, E. Breen2, R. Kefford7, R.A. Scolyer8, G.V. Long3, H. Rizos1

Author affiliations

  • 1 Biomedical Science, Macquarie University, Melanoma Institute Australia, 2113 - Sydney/AU
  • 2 Biomedical Science, Macquarie University, 2113 - Sydney/AU
  • 3 Department Of Medical Oncology, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, 2060 - North Sydney/AU
  • 4 Medical Oncology, The Crown Princess Mary Cancer Centre, Melanoma Institute Australia, Sydney University, 2145 - Westmead/AU
  • 5 Medical Oncology, Melanoma Institute Australia, University of Sydney, 2060 - North Sydney/AU
  • 6 Medical Oncology, The Crown Princess Mary Cancer Centre, 2145 - Westmead/AU
  • 7 Clinical Medicine, Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney/AU
  • 8 Pathology, Royal Prince Alfred Hospital, Melanoma Institute Australia, Sydney University, 2050 - Camperdown/AU
More

Resources

Abstract 4820

Background

Immune checkpoint inhibitors improve survival of patients with advanced melanoma. Combination anti-PD1 and anti-CTLA4 therapy improves the response rate compared to single agent anti-PD1, at the expense of far greater toxicity. While efforts have been made to identify biomarkers to predict treatment response, there are no biomarkers to predict for immunotherapy toxicity.

Methods

198 plasma samples from 99 patients (discovery cohort – 50 patients, validation cohort – 49 patients) receiving combination anti-PD1 (nivolumab or pembrolizumab) and anti-CTLA4 (ipilimumab) were studied. The expression of 65 cytokines, measured at baseline (PRE) and early during treatment (EDT: week 1-3), was correlated with immune-related toxicity, defined as toxicity that warranted discontinuation of treatment and administration of high dose steroids (≥ 50mg PO prednisolone equivalent), within 6 months of starting treatment (hypophysitis requiring steroid replacement was excluded).

Results

Toxicity rates were comparable between the discovery and validation cohorts, 21/50 (42%) and 22/49 (45%) respectively. The median expression of all 65 cytokines was significantly higher in patients with immune-related toxicity, compared to patients without toxicity in both the discovery cohort (PRE; p = 0.01, EDT; p < 0.01) and validation cohort (PRE; p = 0.03, EDT; p = 0.02). In addition, the median expression of six pro-inflammatory cytokines associated with autoimmune disease (IFN, IL-2, IL-17A, IL-1α, IL-1β, IL12) was significantly higher at baseline and EDT in patients with toxicity; discovery (PRE and EDT, p < 0.01) and validation (PRE, p < 0.01; EDT, p = 0.01). Expression of FGF-2, IL-12P70, IL13, IL-1 β, IL-2, MIL-1β and VEGF-A was also significantly higher in patients with toxicity at PRE and EDT, in both the discovery and validation cohorts, compared to patients without toxicity.

Conclusions

Elevated levels of circulating cytokines at baseline and EDT predict development of immune-related toxicity. Pre-treatment measurement of circulating inflammatory cytokines may have an important role in treatment selection for metastatic melanoma patients.

Clinical trial identification

Legal entity responsible for the study

Macquarie University.

Funding

National Health and Medical Research Council.

Editorial Acknowledgement

Disclosure

A.M. Menzies: Consultant or advisory role: BMS, MSD, Novartis, Roche, Pierre-Fabre; Honoraria: BMS, MSD, Novartis, Roche. M.S. Carlino: Consultant or advisory role: MSD, BMS, Amgen, Novartis; Honoraria: BMS, Novartis, MSD A. Guminski: Consultant or advisory role: BMS, Roche, Sun Pharma, Merck KgA Travel support: BMS, Sun Pharma. R. Kefford: Consultant or advisory role: BMS, Merck; Honoraria: BMS Conference attendance: BMS, Amgen. G.V. Long: Consultant or advisory role: BMS, Novartis, Roche, Amgen, Pierre Fabre, MSD, Array; Honoraria: BMS, MSD, Roche, Novartis, Incycte. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings